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Abstract: A3 adenosine receptor (AR) is a G protein-coupled receptor 
(GPCR) overexpressed in the membrane of specific cancer cells. 
Thus, the development of nanosystems targeting this receptor could 
be a strategy to both treat and diagnose cancer. Fe-filled carbon 
nanotubes (CNTs) are an optimal platform for theranostic purposes, 
and the use of a magnetic field can be exploited for cancer magnetic 
cell sorting and thermal therapy. In this work, we have conjugated an 
A3AR ligand on the surface of Fe-filled CNTs with the aim to target 
cells overexpressing A3ARs. In particular, two conjugates bearing 
PEG linkers of different length were designed. A docking analysis on 
the A3AR showed that both CNT and linker do not interfere with ligand 
binding to the receptor, that was confirmed by in vitro preliminary 
radioligand competition assays on A3AR. Encouraged by this result, 
magnetic cell sorting was applied to a mixture of cells overexpressing 
or not the A3AR where our compound displayed indiscriminate binding 
to all cells. Despite this, it is the first time that a GPCR ligand was 
anchored to a magnetic nanosystem, thus it opens the door to new 
applications for cancer treatment. 
 
Introduction 
Adenosine is a purine nucleoside that mediates numerous 
essential physiological functions by interacting with adenosine 
receptors (ARs), which belong to the family of G-protein-coupled 
receptors (GPCR).[1] Adenosine is involved in neuronal, cardiac 
and immune processes, as well as in inflammation and cancer.[2–
5] Four different ARs subtypes have been discovered to date and 
classified as A1, A2A, A2B and A3.[6] High extracellular adenosine 
concentration (in the micromolar range), which is able to stimulate 
all the AR subtypes, is commonly found in the tumor 
microenvironment due to hypoxia or cell damages.[7,8] Cells 
generally co-express multiple AR subtypes on their membrane 
and their specific response to adenosine is dictated by a particular 
AR expression pattern.[9] The precise role of A3AR in tumor 
development is not yet fully clarified. Whereas on one hand A3AR 
stimulation has been found to inhibit prostate carcinoma cells 
proliferation and induce cell death in myeloid and lymphoid cell 
lines,[10,11] it has been shown on the other hand that such 
stimulation could enhance glioblastoma cell invasion and favour 
colon tumour cell proliferation.[12,13] Also, A3AR has been found to 
be up-regulated (up to 2.3 fold compared to normal tissues) in a 
wide range of tumours such as colon, prostate or skin 
carcinoma.[10,14,15] Moreover, it has been shown that A3AR 
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expression levels directly correlate to cancer severity.[16,17] 
Therefore, the A3AR could be considered as a marker for this kind 
of tumours and it is possible to take advantage of this to develop 
therapeutic and/or diagnostic systems able to specifically target 
this receptor. 
The demonstration of the existence of ARs dimers and oligomers 
makes ARs an attractive target for multivalent nanoparticles.[18–20] 
In fact, the presence of multiple ligands on the same platform 
could bridge the different binding sites present in GCPR 
multimeric architectures. The resulting stabilization of the system 
could ameliorate or lead to different pharmacodynamics and 
pharmacokinetic properties in comparison to the monomeric 
ligands.[21] In this respect, Jacobson and co-workers developed a 
series of polyamidoamine (PAMAM) dendrimers displaying 
multiple AR ligands.[21–26] In particular, when an A3 ligand was 
conjugated to a G4 PAMAM dendrimeric core, a dramatic 
enhancement of both selectivity and affinity was achieved when 
compared to the ligand alone.[25] Gold nanoparticles were also 
used as platforms to modulate adenosine receptors by 
conjugation with both agonists and antagonists.[27] Moreover, the 
use of multivalent nanostructures allows the integration of other 
relevant components for therapeutic, diagnostic and monitoring 
purposes.[24,28,29]  
In this context, carbon nanostructures, and in particular carbon 
nanotubes (CNTs) have been proposed as complementary 
multifunctional nanostructures in nanomedicine for imaging, 
tissue engineering, drug delivery and anticancer platforms.[30–39] 
Particularly appealing are Fe-filled carbon nanotubes (Fe@CNTs), 
as they display multimodal functionality for filtration/separation of 
biological species, magnetic drug-targeting and/or delivery, 
magnetic resonance imaging, and localized magnetic fluid 
hyperthermia-based treatments.[40–42] Recently, our group used 
Fe@CNTs conjugated with the antibody Cetuximab targeting a 
plasma membrane receptor (EGFR) overexpressed in cancer 
cells.[43] In vitro experiments showed that the magnetic hybrids 
efficiently sort cancer cells from populations of healthy cell lines 
and selectively suppress them through magnetic fluid 
hyperthermia (MFH) upon application of an alternating magnetic 
field.[44] Building on these results, in this work we report on the use 
of Fe@CNTs conjugates for targeting A3AR. Fe@CNTs were 
conjugated to a A3AR antagonist (1) with a pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]-pyrimidine (PTP) core (Fig. 1), which contemporary 
bears a conjugable carboxylic group and a good affinity and 
selectivity towards A3AR at the same time.[45] Competition binding 
assays were performed to evaluate the affinity of Fe@CNTs-
PEG-PTP for A3ARs. Finally, derivatives were used for 
preliminary in vitro evaluation of their magnetic sorting 
effectiveness of cells overexpressing A3AR. 
 
Figure 1. Structure of the potent A3 AR antagonist 1 and of the conjugate with 
Fe@CNTs (2,3). 
Results and Discussion 
Bioconjugation approach and design  
The replacement of a large water-solubilizing protein (antibody) 
by a smaller hydrophobic ligand (A3AR antagonist) suggests to 
use water solubilizing linkers such as polyethylene glycol (PEG) 
chains between the Fe@CNT surface and antagonist 1, this in 
order to enhance conjugate water solubility. Besides the positive 
effect of keeping good dispersion properties, PEG chains act as 
spacers to avoid the disruption of the ligand affinity towards A3AR 
by a potential steric clash. Two PEG chains were used (tri- or 
hexaethyleneglycol, TEG or HEG) to study the steric impact on 
the conjugate properties (2,3). The synthetic route towards 
Fe@CNTs-PEG-PTP derivatives 2 and 3 can be divided into two 
parts: first, the synthesis of aniline linkers 4 and 5 (Scheme 1), 
and second the covalent grafting onto the Fe@CNTs. This allows 
the subsequent conjugation of CNTs with PTP carboxylic acid 
ligand 1 (Scheme 2). In order to assess the perturbation on the 
A3AR affinity caused by the presence of the PEG, we also 
synthetized (Scheme S1) references TEG-PTP (6) and HEG-PTP 
(7). 
Computational validation of the CNT-based architecture 
A in silico model of the CNT functionalized with a single PEG-PTP molecule was 
built as a proof of concept that the conjugates geometries were able to 
guarantee the PTP accommodation on the binding site of human A3AR without 
any steric clash due to the presence of the carbon tubular structure.[[46]] First, 
we docked PTP on an apo conformation of A3AR obtained by homology 
modeling from the closely related human A2A AR. The docking simulation 
resulted in a bound conformation comparable to previously reported studies on 
this scaffold.[[47]] Then, we designed an empty CNT (34320 atoms) having a 
length of 350 Å and a diameter of around 80 Å to which we decorated a single 
linker of TEG and HEG. The PTP-A3AR was conjugated to PEG-CNTs, leading 
to the CNTs-PEG-PTP model inserted on the A3AR binding site. 
 
Figure 2. In silico model of CNT-HEG-PTP bound to hA3AR. HEG-PTP are 
colored with green carbon atoms while the A3AR receptor is displayed as a pink 
ribbon. Only a section of the POPC bilayer (gold surface) is showed to facilitate 
the receptor visualization. 
Finally, to mimic the presence of the cell membrane, the complex 
was embedded in a phosphatidylcholine bilayer. The whole 
system (Fig. 2) shows that the CNT framework does not affect the 
PTP binding. One should also note that the PEG linker does not 
guarantee wide freedom in the PTP mobility, that could be 
eventually restored by further extending the PEG linker. 
Synthesis of aniline linkers 
The synthesis of anilines 4 and 5 started with the mono-tosylation 
of commercially available triethylene (TEG) and hexaethylene 
(HEG) glycols. In the first case, affordable TEG was used in large 
excess (8 eq.) affording mono-tosylated TEG 8 in near-
quantitative yield. On the other hand, the expensive HEG 
substrate was reacted in stoichiometric amounts with tosyl 
chloride, using Et3N as a base, to give desired mono-tosylated 
HEG 9 in modest yield (34%) due to the unavoidable formation of 
the bis-tosylated derivative. Molecules 8 and 9 were reacted with 
NaN3 in DMF, to generate azides 10 and 11 in excellent yields 
(80% and quantitative, respectively). Subsequent tosylation of the 
remaining hydroxyl functionality, gave compounds 12 and 13 that, 
followed by Williamson etherification with p-nitrophenol, were 
transformed into nitro derivatives 14 and 15 in very good yields 
(85% and 92%, respectively) over the two steps. Simultaneous 
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reduction of both azido and nitro groups with H2 and Adam’s 
catalyst (PtO2) gave the amine derivatives 16 and 17 in very good 
yields (94% and 92%, respectively). Building on the different 
reactivity of the terminal alkyl amines compared to arylamines, 
chemoselective protection of compounds 16 and 17 with BOC-
anhydride afforded 4 and 5 in good yields (66 and 69%, 
respectively). Small amounts (7%) of bis-protected HEG by-
product 18 were also isolated, whereas bis-protected TEG 
derivative was detected in a small amount in the reaction mixture 
and not isolated.  
Scheme 1. Synthesis of aniline linkers 4 and 5. Reagents and conditions: i) 
TsCl, KOH, dichloromethane, 0 °C to r.t., 8 h; ii) NaN3, DMF, 60 °C, overnight; 
iii) p-nitrophenol, K2CO3, DMF, 60 °C, overnight; iv) PtO2 (1 mol %), H2 (1 atm), 
methanol, r.t., overnight; v) Boc2O, THF, r.t., 16 h. 
In a second stage, anilines 4 and 5 were grafted onto raw 
Fe@CNTs under the conditions described by Tour and 
coworkers,[[48]] i.e. in-situ reaction with isoamyl nitrite and CNTs, 
giving respectively Fe@CNTs-TEG-NHBoc (19) and Fe@CNTs-
HEG-NHBoc (20) (Scheme 2).  
A test reaction was performed on linker 5 to check the BOC-
deprotection conditions. It was found that using a 1.5 M solution 
of HCl in MeOH and water was sufficient to achieve a complete 
BOC deprotection in one night at rt. Fe@CNTs-PEG-NHBoc 
derivatives 19 and 20 were deprotected into corresponding 
Fe@CNTs-PEG-NH2 derivatives 21 and 22. All four CNT 
derivatives (19-22) were characterized by XPS, revealing new 
peaks at 400.0 eV attributed to the N 1s binding energy of the 
amino-terminated PEG chains (Figs. 3C-3D). Grafting of PEG 
linkers provoked a doubling of detected O 1s atomic percentages 
(from about 3 to 6 %, Table 1) in Fe@CNTs-PEG-NHBoc (19,20) 
and Fe@CNTs-PEG-NH2 (21,22) compared to pristine Fe@CNTs. 
Linkers grafting onto Fe@CNTs 
In a second stage, anilines 4 and 5 were grafted onto raw 
Fe@CNTs under the conditions described by Tour and 
coworkers,[[48]] i.e. in-situ reaction with isoamyl nitrite and CNTs, 
giving respectively Fe@CNTs-TEG-NHBoc (19) and Fe@CNTs-
HEG-NHBoc (20) (Scheme 2).  
A test reaction was performed on linker 5 to check the BOC-
deprotection conditions. It was found that using a 1.5 M solution 
of HCl in MeOH and water was sufficient to achieve a complete 
BOC deprotection in one night at rt. Fe@CNTs-PEG-NHBoc 
derivatives 19 and 20 were deprotected into corresponding 
Fe@CNTs-PEG-NH2 derivatives 21 and 22. All four CNTs 
derivatives (19-22) were characterized by XPS, revealing new 
peaks at 400.0 eV attributed to the N 1s binding energy of the 
amino-terminated PEG chains (Figs. 3C-3D). Grafting of PEG 
linkers provoked a doubling of detected O 1s atomic percentages 
(from about 3 to 6 %, Table 1) in Fe@CNTs-PEG-NHBoc (19,20) 
and Fe@CNTs-PEG-NH2 (21,22) compared to pristine Fe@CNTs. 
Scheme 2. Synthesis of Fe@CNTs-PEG-PTP systems (2,3). A. Reagents and 
conditions: i) Fe filled CNTs, isoamyl nitrite, NMP, 90 °C, 20 h; ii) HCl, methanol, 
r.t., 16 h; iii) 23, DMF, TEA, r.t., 14 h. B. Reagents and conditions: i) NHS, 
EDC.HCl, DMAP, DMF, r.t., 48 h. 
TGA (thermogravimetric analysis) measurements performed 
under air also evidenced a successful functionalization of the 
carbon framework, displaying an enhanced weight loss of about 
4-5 wt% at 400 °C compared to pristine Fe@CNTs (Fig. 4), after 
a pyrolysis event occurring between 200 and 350 °C for 
Fe@CNTs-PEG-NHBoc (19,20) and Fe@CNTs-PEG-NH2 
(21,22). This pyrolysis event can be related to the thermal 
decomposition of the PEG chain as it is retrieved in the TGA 
analysis of reference Boc-HEG-aniline 5 (Fig. 4B). Precise 
quantification of the functionalization degree based on a triplicate 
of TGA runs per compound was attempted (Table 1) and gave 
values of 356 ± 75 and 186 ± 49 μmol·g-1 for Fe@CNTs-TEG-NH2 
(21) and Fe@CNTs-HEG-NH2 (22), respectively. As the values 
obtained by TGA showed a high variability (RSD > 21%), we 
performed complementary elemental analyses (Table 1) to obtain 
a free amino group content of 109 ± 7 and 88 ± 0 μmol·g-1 for 
CNTs-TEG-NH2 (21) and Fe@CNTs-HEG-NH2 (22), respectively. 
Conjugation of A3AR antagonist to Fe@CNTs-PEG-NH2 
PTP was firstly reacted with N-hydroxysuccinimide (NHS) in the 
presence of catalytic amount of DMAP,[[45]] to afford NHS 
activated ester 23 in 44% yield (Table S1, entry 2; Scheme 2B).  
It is important to note that NHS ester 23 is rather unstable either 
as a solid or dissolved in DMSO and was consequently 
synthesized and isolated only in the required amounts and directly 
conjugated to Fe@CNTs-PEG-NH2 derivatives (21,22).  
Amide reaction coupling between 23 and the Fe@CNTs-PEG-
NH2 derivatives (21,22) in DMF in the presence of Et3N yielded 
final bioconjugates Fe@CNTs-TEG-PTP (2) and Fe@CNTs-
HEG-PTP (3) (Scheme 2A). 
The conjugation of PTP 1 to Fe@CNTs-PEG-NH2 (21,22) was 
confirmed and quantified by a combination of XPS (X-ray 
photoelectron spectroscopy), TGA and EA (elemental analysis) 
techniques. In particular, XPS survey spectra displayed a 
substantial 2-fold increase in the N 1s atomic percentages when 
passing from Fe@CNTs-PEG-NH2 (21,22) to Fe@CNTs-PEG-
PTP (2,3) (Table 1). The XPS spectra of Fe@CNTs-PEG-PTP 
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conjugates 2 and 3 display a peak centered at 399.5 eV with a 
shoulder at 401.0 eV in the N 1s region. This shape is a signature 
of the presence of PTP ligand 1 (Fig. 3). 
Figure 3. N 1s (left) and O 1s (right) XPS spectra of PTP ligand 1 (A), Fe@CNTs 
(B), Fe@CNTs-HEG-NHBOC 20 (C), Fe@CNTs-HEG-NH2 22 (D) and 
Fe@CNTs-HEG-PTP 3 (E). Peak maximum of PTP 1 is denoted with a green 
star (399.5 eV) and the “shoulder’ with a black dot (401.0 eV). Peak maxima of 
Fe@CNTs-HEG-NHBOC 20 and Fe filled-CNTs-HEG-NH2 22 are denoted with 
a red square (400 eV). 
TGA of Fe@CNTs-PEG-PTP (2,3) performed under air showed 
the presence of two additional pyrolysis events compared to 
Fe@CNTs-PEG-NH2 (21,22) (Fig. 4) at 280 °C and 350 °C which 
are also retrieved in the TGA profile of ligand 1. Attempts to 
estimate the PTP content in Fe@CNTs-PEG-PTP derivatives 
(2,3) over three TGA runs were affected by high variability (RSD 
> 63%). To reach a better precision, the elemental composition of 
Fe@CNTs-PEG-NH2 (21,22) and Fe@CNTs-PEG-PTP (2,3) was 
determined by EA on duplicates, obtaining values associated with 
low RSD (> 3%). The increase in N-content related to the 
conjugation of 1 was employed to estimate the loading of PTP 
(Table 1). Interestingly, we have observed by this technique that 
Fe@CNTs-HEG-PTP (3) display about two times more PTP 
ligand (34.0 ± 0.7 μmol·g-1) than do Fe@CNTs-TEG-PTP (2, 
16.1± 0.5 μmol·g-1). The estimate unreacted fractions of amino 
groups in Fe@CNTs-TEG-PTP (2) and Fe@CNTs-HEG-PTP (3) 
were 85% and 61%, respectively. 
Table 1. XPS, TGA and EA characterization data for Fe@CNTs, Fe filled-CNTs-
PEG-NH2 21,22 and Fe filled-CNTs-HEG-PTP 2,3. XPS atomic percentages 
were calculated on spectra recorded from three different spots of the same 
sample and expressed as mean ± S.D. N wt% were measured by EA and are 



























CNTs 97.11  ± 0.52 n.d. 
2.89  
± 0.52 n.a. n.a. 
0.0 
± 0.0 n.a. 






± 75 n.a. 
109.0  
± 7.0 n.a. 






± 49 n.a. 
88.3  
± 0.0 n.a. 























± 0.7 [b] 
34.0  
± 0.7 
[a] Electron configuration of the detected electron within the atom.  
[b] Difference between initial free amines and PTP contents. 
Figure 4. TGA profiles under air displayed as temperature-modulated weight% 
(–––) and differential weight% (----) of (A) Fe@CNTs, (B) compound 5, (C) 
Fe@CNTs-HEG-NHBOC 20, (D) Fe@CNTs-HEG-NH2 22, (E) PTP ligand 1, 
and (F) Fe@CNTs-HEG-PTP 3. The pyrolysis event associated with the 
decomposition of the PEG chain is indicated with a red square and those 
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associated with decomposition of ligand 1 with a green star (280 °C) and a black 
circle (350 °C). 
Competition binding experiments of Fe@CNTs-PEG-PTP on 
the A3AR  
In order to evaluate the ability of the Fe@CNTs-PEG-PTP 
conjugates to target A3ARs, preliminary binding experiments to 
determine their affinity to the receptor were carried out (Fig. 5). 
Figure 5. Preliminary displacement binding experiments of Fe-filled-CNTs-
TEG-PTP (2), Fe-filled-CNTs-TEG-NH2 (21), TEG-PTP (6), Fe-filled-CNTs-
HEG-PTP (3), Fe-filled-CNTs-HEG-NH2 (22) and HEG-PTP (7), at different 
concentrations: 0.3, 1, 3 and 10 μM (for CNTs the concentrations are based on 
calculated PTP content or on the same weight amount as for the derivatized 
material for control Fe filled-CNTs-PEG-NH2). N = 1 for all conditions. 
Succinctly, these tests measure competition of Fe@CNTs-PEG-
PTP conjugates (2,3) for binding of a radioactively labeled A3AR 
selective agonist, [3H]HEMADO at human A3ARs. Reference 
measurements were performed with Fe@CNTs-PEG-NH2 
derivatives 21 and 22, and with TEG-PTP and HEG-PTP 
comparators 6 and 7 (Scheme S1).[[49,50]] The different 
concentrations studied were 0.3, 1, 3 and 10 μM. For the CNT 
bioconjugates, the concentrations were estimated on calculated 
PTP content and the reference Fe@CNTs-PEG-NH2 (21,22) were 
tested using the same weight. Fig. 5 depicts the results of the 
[3H]HEMADO displacement experiments. Clearly, both 
Fe@CNTs-TEG-PTP (2) and Fe@CNTs-HEG-PTP (3) compete 
efficiently with the radioligand. 
Looking at 10 μM, one can see that Fe@CNTs-PEG-PTP 2 and 
3 displaced more [3H]HEMADO (about 90%) than non-targeting 
Fe@CNTs-PEG-NH2 (21,22), although some non-specific binding 
interactions were observed with 19 and 20 as well. Interestingly, 
our Fe@CNTs-PEG-PTP (2,3) were more potent than 
comparators TEG-PTP 6 and HEG-PTP 7 at 10 μM. Finally, the 
Ki values of PEGylated derivatives TEG-PTP 6 and HEG-PTP 7 
were 322 and 531 nM (preliminary data, n=1), respectively. These 
values are not so far from Ki value of the parent compound 1 (128 
nM),[45] meaning that PEG chains have a negligible effect on the 
binding affinity of PTP towards human A3AR. 
Magnetic cell sorting effectiveness of Fe@CNTs-PEG-PTP 
In-vitro biological assessment of the ability of Fe@CNTs-HEG-
PTP (3) to fish out targeted cells was carried out. Specifically, 
Fe@CNTs-HEG-PTP (3) were mixed with either stable 
transfected A3AR-overexpressing CHO cells or wild-type CHO 
cells (Figs. 6 and7) and the resulting suspension submitted to a 
static magnetic field. Surprisingly, we observed that both cell lines 
were extensively removed from the medium with a strong 
preference for the non-targeted CHO WT. To gain more insights 
into the binding mode of Fe@CNTs-HEG-PTP (3), we also tested 
their ability to fish human epidermoid carcinoma cells (A431) and 
human endothelial EA.hy926 cells (EA) (Figs. 6 and 7) as 
negative controls. A431 cells were chosen because they were 
reported to not overexpress A3AR[4] and EA cells because they 
are no cancer cells. Interestingly, we observed that A431 cells 
were removed faster and to a higher extent than EA cells. In 
parallel, the selective magnetic removal of A3AR+ vs. A3AR- cells 
in a mixture was assayed by confocal fluorescence microscopy. 
Specifically, CHO cells were fluorescently stained with different 
colours (green for CHO WT and red for CHO A3AR), mixed with 
Fe@CNTs-HEG-PTP 3 and placed against a magnet for 8 
minutes (Fig. 8). 
Figure 6. Magnetic cell sorting effectiveness (CFE) of CHO A3AR (n=2), CHO 
WT (n=3), A431 (n=3) and EA (n=3) cells by Fe filled-CNTs-HEG-PTP (3). 
Results are expressed as mean ± S.D. The magnetic cell sorting effectiveness 
is defined as the percentage of cells fished out of a solution upon application of 
a given static magnetic field gradient at a given time. 
We observed that both cell lines were removed, with only a few 
cells remaining in the supernatant after the magnetic manipulation. 
As a further control, the same experiment was repeated with non-
targeting Fe@CNTs-HEG-NH2 derivative 22 (Fig. 8). Under these 
conditions, we noted the nearly complete absence of both A3AR 
and WT CHO cells in the supernatant after 8 minutes of magnetic 
filtration, suggesting that an enhanced cell binding and removal 
could be achieved compared to Fe@CNTs-HEG-PTP 3. Together, 
these results suggest that Fe@CNTs-HEG-PTP 3 possess a high 
degree of non-specific binding. Interestingly, the preferential 
binding of Fe@CNTs-HEG-PTP 3 to A431 cells compared to EA 
cells along with the presence of remaining cationic free amino 
groups, suggests an important role played by electrostatic 
interactions. The enhanced non-specific magnetic fishing with 
Fe@CNTs-HEG-NH2 22 is in line with this hypothesis as it could 
be ascribed to their higher content in cationic amino groups 
compared to Fe@CNTs-HEG-PTP (3). Also, previous works 
reported a high level of adsorption of positively-charged 
nanoparticles on negatively-charged mammal cell surfaces or 
negatively-charged model membranes.[[51,52],[53]] In particular, 
Soukos et al. observed a preferential adsorption of cationic 
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polylysine polymers onto A431 cells compared to EA cells, in 
agreement with our observations.[52] This binding selectivity has 
been attributed to the overexpression of anionic polysialic acid 
residues in cancer cell membranes compared to other type cell 
models.[51] In addition, even if compounds 3 and 22 were 
incubated with cells for a very short time, an indiscriminate uptake 
of CNTs by cells could not be excluded. Thus, this could be 
another reason explaining the lack for selectivity of synthesized 
structures. 
Figure 7. Optical microscopy images showing the cell density in the supernatant after 0 (1), 60 (2), 120 (3), 240 (4) and 480 (5) seconds of magnetic sorting of CHO 
A3AR, CHO WT, A431 and EA cells by Fe@CNTs-HEG-PTP 3. Scale bar = 250 μm (all the images are at the same scale). 
 
Figure 8. Confocal microscopy images of (1) an initial mixture of Fe@CNTs-HEG-PTP 3 (panel A) or Fe@CNTs-HEG-NH2 22 (panel B), CHO A3AR (red) and CHO 
WT (green) cells and of the supernatant (2) and the magnetic precipitate (3) after 8 minutes of magnetic filtration. 
 
Conclusion 
The adenosine A3 receptor holds an important role in cancer 
development and is over-expressed in a number of tumor tissues. 
In addition, the membrane localization of A3ARs and their 
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existence in di- and oligomeric forms make them good candidates 
for a multivalent targeting cancer treatment. In this respect, this 
work focused on the conception of a novel multivalent Fe@CNTs 
tool conjugated to a small organic A3AR ligand 1, possessing a 
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidine (PTP) core, for the 
selective targeting of human A3AR-overexpressing cells. Our 
strategy involved the formation of a peptidic bond between Fe 
filled-CNTs and carboxylic acid 1 through two amino-terminated 
PEG spacers (TEG and HEG), giving Fe filled-CNTs-TEG-PTP 
(2) and Fe filled-CNTs-HEG-PTP (3). These conjugates showed 
good A3AR binding affinity in binding studies (displacement > 80% 
at 10 μM) unlike control Fe filled-CNTs-PEG-NH2 21 and 22, thus 
demonstrating that our conjugation strategy maintains the affinity 
of the ligand against its target. The ability of Fe filled-CNTs-HEG-
PTP (3) to selectively target and shepherd A3AR+ vs. A3AR- cells 
was also evaluated in vitro. Interestingly, the opposite selectivity 
was observed. This effect was further investigated and ascribed 
to the formation of electrostatic interactions between unreacted 
cationic free amino groups on Fe filled-CNTs-HEG-PTP (3) and 
anionic residues on cell membranes. These findings further 
suggest that the surface chemistry is a key component of a 
nanomaterial for its ability to bind a receptor embedded in a cell 
membrane and thus the careful choice of the nanostructure 
exosurface functionalization has to be made.[54–57] Even if further 
development is needed to obtain a nano-tool able to shepherd 
A3AR overexpressing cancer cells, this work opens the door to the 




Thin layer chromatography (TLC) was conducted on pre-coated aluminum 
sheets with 0.20 mm Macherey-Nagel Alugram SIL G/UV254 with 
fluorescent indicator UV254. Column chromatography was carried out 
using Merck Gerduran silica gel 60 (particle size 40-63 μm). Melting points 
(M.p.) were measured on a Büchi Melting Point B-545 in open capillary 
tubes and have not been corrected. Nuclear magnetic resonance (NMR) 
1H, 13C spectra were obtained on a 500 MHz (Jeol JNM ECZR-500) or 400 
MHz NMR (Jeol JNM EX-400). Chemical shifts were reported in ppm using 
the solvent residual signal as an internal reference. Coupling constants (J) 
were given in Hz. Resonance multiplicity was described as s (singlet), d 
(doublet), t (triplet), dd (doublet of doublets), q (quartet), m (multiplet) and 
br (broad signal). Carbon spectra were acquired with a complete 
decoupling for the proton. The Delta 5 software (Jeol) was used for data 
processing. Infrared spectra (IR) were recorded on a Perkin-Elmer 
Spectrum II FT-IR System with Specac Silver Gate Evolution single-
reflection ATR mounted with a diamond crystal. Mass spectrometry (MS) 
was performed either by the Centre de spectrométrie de masse at the 
Université de Mons in Belgium were they performed high-resolution ESI-
MS (HRMS) and MALDI-MS, or by the Fédération de Recherche 
ICOA/CBM (FR2708) platform of Orléans in France, where they performed 
high-resolution ESI-MS (HRMS). ESI-MS measurements at the Université 
de Mons were performed on a Waters QToF2 mass spectrometer 
operating in positive mode. High-resolution ESI mass spectra (HRMS) at 
Orléans were performed on a BrukermaXis Q-TOF in the positive ion mode. 
Data were processed using BrukerDataAnalysis 4.1 software. 
Thermogravimetric analyses (TGA) were performed using a TGA Q500 
(TA Instruments), treating the samples placed in Pt pans with the following 
procedure: isotherm at 100°C for 20 min (to remove residual solvent, if 
any), ramp from 100 to 800°C at 10°C∙min-1, under nitrogen or air (flow 
rate on the sample of 90 mL∙min-1). X-Ray photoelectron spectroscopy 
(XPS) analyses were performed on a Thermo Scientific K-Alpha XPS 
system (Thermo Fisher Scientific). For each analysis, about 0.5 mg of 
material were deposited on a copper thin film, which was then fixed on an 
XPS sample holder using a double side adhesive conductive carbon tap 
(SPI supplies). Spectra were collected using a monochromatized Al-K α 
radiation (1486.6 eV). The surface normal emitted photoelectron was 
analyzed in a double-focusing hemispherical analyzer and recorded on a 
multi-channel detector. All the spectra were acquired in the constant 
analyzer energy mode. The Thermo Scientific Avantage software (Thermo 
Fisher Scientific) was used for digital acquisition and data processing. 
Optical Microscopy images of cells were acquired with a Leitz Labovert FS 
optical microscope equipped with a Leica DFC290 camera. Confocal 
Fluorescence Microscopy images of cells were acquired with a Leica SP5 
microscope. Elemental analysis (EA) (C,H,N) was performed on a Thermo 
Finnigan-Flash EA 1112. 
Synthetic procedures 
The Fe@CNTs used in this work are obtained by in situ procedure 
employing chemical vapour deposition methodology followed by washings 
with hydrochloric acid as reported in our previous work.[44] Compound 1 
was obtained following previously reported procedures.[45,58] 
Synthesis of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 8. To a solution of tri-ethyleneglycol (29.82 g, 
0.199 mol) in THF (12.5 mL) was added a solution of sodium hydroxide 
(1.587 g, 0.0396 mol) in water (9.5 mL). The resulting mixture was stirred 
at room temperature for 10 min and then cooled at 0 °C. A solution of tosyl 
chloride (4.738 g, 0.0248 mol) in THF (31 mL) was added dropwise over 1 
h, the resulting mixture stirred 2 hours at 0 °C, let warmed to room 
temperature and stirred for additional 4 hours. The reaction mixture was 
diluted with water (100 mL) and dichloromethane (50 mL) and the aqueous 
phase extracted with dichloromethane (5 × 50 mL), the combined organic 
layers were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure to afford desired compound 8 as a yellow oil (7.450 g, 
0.0245 mol, 99%). 1H-NMR (CDCl3): δ 7.79 (d, 2H, J=8.3 Hz), 7.33 (d, 2H, 
J=8.3 Hz), 4.17-4.15 (m, 2H), 3.72-3.57 (m, 10H), 2.44 (s, 3H). 1H peak 
missing. 13C-NMR (CDCl3): δ 144.98, 133.00, 129.94, 128.06, 72.69, 
72.56, 70.87, 70.47, 70.39, 69.27, 68.79, 61.78, 21.75. Characterization in 
agreement with previously reported data.[59] 
Synthesis of 17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl 4-
methylbenzenesulfonate 9. To a cooled (0 °C) solution of hexa-
ethyleneglycol (10 g, 35.5 mmol) and triethylamine (2.8 mL, 20 mmol) in 
THF (100 mL) was added tosyl chloride (6.76 g, 35.4 mmol, 0.98 eq.) in 
small portions (about 100 mg). This mixture was allowed to reach room 
temperature and stirred overnight. The reaction mixture was diluted with 
chloroform (60 mL) and extracted with 1M HCl (3 × 60 mL), brine (1 × 60 
mL), dried over magnesium sulfate and concentrated under reduced 
pressure. The crude was purified by silica gel chromatography 
(dichloromethane 100% to dichloromethane/methanol 95:5) to afford the 
desired compound 9 as a yellow oil (5.21 g, 12 mmol, 34%). 1H-NMR 
(CDCl3): δ 7.80 (d, 2H, J=8.1 Hz), 7.34 (d, 2H, J=8.1 Hz), 4.16-4.14 (m, 
2H), 3.80-3.58 (m, 22H), 2.44 (s, 3H). 1H peak missing. 13C-NMR (CDCl3): 
δ 144.93, 133.06, 129.95, 128.12, 72.73, 70.81, 70.65, 70.62, 70.35, 69.42, 
68.80, 67.80, 21.79. Peaks missing due to overlaps in the PEG region. 
Characterization in agreement with previously reported data.[60] 
Synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol 10. To a solution of 
tosylate 8 (5 g, 16.4 mmol) in anhydrous DMF (10 mL) was added sodium 
azide (10.68 g, 164.5 mmol) under a flux of argon. The resulting mixture 
was stirred at 60 °C for 5 hours, concentrated under reduced pressure and 
diluted with water (50 mL) and dichloromethane (50 mL). The aqueous 
phase was extracted with dichloromethane (5 X 50 mL) and the combined 
organic layers dried over magnesium sulfate and concentrated under 
reduced pressure to afford desired compound 10 as a yellow oil (2.325 g, 
13.2 mmol, 81%). 1H-NMR (CDCl3): δ 3.72-3.66 (m, 8H), 3.61-3.59 (m, 2H), 
3.39-3.37 (m, 2H), 2.38 (br s, 1H). 13C-NMR (CDCl3): δ 72.59, 70.76, 70.50, 
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70.16, 61.87, 50.75. Characterization in agreement with previously 
reported data.[61] 
Synthesis of 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 11. To a 
solution of tosylate 9 (2 g, 4.58 mmol) in anhydrous DMF (4 mL) was added 
sodium azide (2 g, 30.8 mmol) under a flux of argon. The reaction mixture 
was stirred 20 hours at 60 °C, concentrated under reduced pressure and 
the crude suspended in dichloromethane and filtered through cotton. The 
precipitate was washed with several portions of dichloromethane and the 
filtrate concentrated under reduced pressure to afford desired compound 
11 as a colorless oil (1.4074 g, 4.58 mmol, quantitative). 1H-NMR (CDCl3): 
δ 3.64-3.62 (m, 2H), 3.60-3.56 (m, 18H), 3.53-3.51 (m, 2H), 3.32-3.30 (m, 
2H), 2.96 (s, 1H). 13C-NMR (CDCl3): δ 72.45, 70.53, 70.48, 70.44, 70.20, 
69.91, 61.52, 50.54. Peaks missing due to overlaps in the PEG region. 
Characterization in agreement with previously reported data.[62] 
Synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 12. To a solution of azide 10 (1.13 g, 6.45 
mmol) and tosyl chloride (1.23 g, 6.45 mmol) in dichloromethane (11 mL) 
was added powdered potassium hydroxide (1.44 g, 25.8 mmol) in small 
portions. The reaction mixture was stirred at room temperature for 8 hours 
and poured in water (25 mL). The aqueous layer was extracted with 
dichloromethane (2 × 25 mL), the combined organic layers were dried over 
magnesium sulfate and concentrated under reduced pressure to afford 
desired compound 12 as a colorless oil (1.908 g, 5.79 mmol, 90%). 1H-
NMR (CDCl3): δ 7.79 (d, 2H, J=8.3 Hz), 7.34 (d, 2H, J=8.3 Hz), 4.15 (m, 
2H), 3.70-3.57 (m, 8H), 3.37-3.34 (m, 2H), 2.43 (s, 3H). 13C-NMR (CDCl3): 
δ 144.94, 133.07, 129.93, 128.06, 70.89, 70.70, 70.18, 69.36, 68.87, 50.74, 
21.73. Characterization in agreement with previously reported data.[63] 
Synthesis of 17-azido-3,6,9,12,15-pentaoxaheptadecyl 4-
methylbenzenesulfonate 13. To a solution of azido 11 (5.10 g, 16.6 
mmol) and tosyl chloride (3.17 g, 16.6 mmol) in dichloromethane (11 mL) 
was added freshly powdered potassium hydroxide (3.64 g, 65.1 mmol) 
(crushed in a mortar) in small portions. The reaction mixture was stirred at 
room temperature for 8 hours. Then water (30 mL) was carefully added. 
The aqueous layer was extracted with dichloromethane (3 X 30 mL), the 
combined organic layers were dried over magnesium sulfate and 
concentrated under reduced pressure to afford desired compound 13 as a 
colorless oil (7.85 g, 17.0 mmol, quantitative). 1H-NMR (CDCl3): δ 7.79 (d, 
2H, J=8.4 Hz), 7.34 (d, 2H, J=8.4 Hz), 4.17-4.15 (m, 2H), 3.69-3.58 (m, 
20H), 3.38-3.36 (m, 2H), 2.45 (s, 3H). 13C-NMR (CDCl3): δ 144.92, 133.10, 
129.94, 128.10, 70.85, 70.78, 70.73, 70.67, 70.14, 69.37, 68.79, 50.79, 
21.76. Peaks missing due to overlaps in the PEG region. Characterization 
in agreement with previously reported data.[62] 
Synthesis of 1-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-4-nitrobenzene 
14. In a flask under argon containing tosylate 12 (1.9 g, 5.76 mmol), para-
nitrophenol (1.201 g, 8.64 mmol) and potassium carbonate (1.19 g, 8.64 
mmol) was added anhydrous DMF (5mL) via syringe. The reaction mixture 
was stirred at 60°C for 24 h, concentrated under reduced pressure and 
diluted with water (50 mL) and ethyl acetate (30 mL). The organic layer 
was washed with saturated sodium carbonate (5 × 50 mL), until the 
aqueous layer was colorless. The combined organic layers were dried over 
magnesium sulfate, filtered and concentrated under reduced pressure to 
afford desired compound 14 as a yellow oil (1.599 g, 5.40 mmol, 94 %). 
1H-NMR (CDCl3): δ 8.21 (d, 2H, J=9.2 Hz), 6.99 (d, 2H, J=9.3 Hz), 4.23-
4.21 (m, 2H), 3.91-3.89 (m, 2H), 3.76-3.74 (m, 2H), 3.70-3.64 (m, 4H), 
3.39-3.37 (m, 2H). 13C-NMR (CDCl3): δ 163.98, 141.75, 126.02, 114.72, 
71.09, 70.89, 70.29, 69.62, 68.32, 50.81. IR (cm-1): ν 500.6, 532.68, 556.5, 
627.44, 634.87, 657.71, 691.16, 752.89, 847.63, 926.1, 1054.1, 1110.48, 
1174.76, 1261.22, 1299.41, 1339.7, 1452.22, 1497.84, 1511.02, 1593.12, 
1607.77, 1767.92, 2100.52, 2449.8, 2517.74, 2871.04, 3084.26, 3114.35, 
3185.05. MS (HR-LCMS, ESI+): found 297.1194 [M+H]+, C12H17N4O5 
requires 297.1193. 
Synthesis of 1-azido-17-(4-nitrophenoxy)-3,6,9,12,15-
pentaoxaheptadecane 15. In a flask under argon containing tosylate 13 
(105 mg, 0.227 mmol), para-nitrophenol (45.26 mg, 0.325 mmol) and 
potassium carbonate (44.85 mg, 0.325 mmol) was added anhydrous DMF 
(5mL) via syringe. The reaction mixture was stirred at 60 °C for 72 hours, 
concentrated under reduced pressure and diluted with dichloromethane 
(30 mL). The organic layer was washed with a 9:1 (v:v) mixture of a 
saturated solution of potassium carbonate and a solution of NaOH (4.8 M) 
(4 × 30 mL) until the aqueous layer was colorless. The combined organic 
layers were dried over magnesium sulfate, filtered concentrated under 
reduced pressure to afford desired compound as a colorless oil 15 (90 mg, 
0.211 mmol, 92%). 1H-NMR (CDCl3): δ 8.13 (d, 2H, J=9.2 Hz), 6.93 (d, 2H, 
J=9.2 Hz), 4.17 (m, 2H), 3.84 (m, 2H), 3.69-3.60 (m, 18H), 3.33 (m, 2H). 
13C-NMR (CDCl3): δ 163.86, 141.48, 125.80, 114.56, 70.84, 70.61, 70.55, 
70.51, 69.97, 69.31, 68.19, 50.61. Peaks missing due to overlaps in the 
PEG region. IR (cm-1): ν 501.62, 657.38, 691.36, 752.98, 773.01, 847.67, 
942.68, 1053.13, 1107.9, 1174.81, 1260.5, 1299.32, 1339.56, 1452.17, 
1497.89, 1511.26, 1592.87, 1607.43, 2100.53, 2868.34. MS (HR-LCMS, 
ESI+): found 429.1978 [M+H]+, C18H29N4O8 requires 429.1979.  
Synthesis of 4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)aniline 16. To a 
solution of nitrobenzene 14 (1.383 g, 4.67 mmol) in methanol (78 mL) was 
added PtO2 (21 mg, 0.092 mmol). The reaction mixture was stirred 24 h at 
room temperature under an atmosphere of hydrogen and then filtered 
through a pad of celite. The filtrate was concentrated under reduced 
pressure to afford desired compound 16 as a colorless oil (1.026 g, 4.27 
mmol, 91%). 1H-NMR (CD3OD): δ 6.76-6.73 (m, 2H), 6.72-6.68 (m, 2H), 
4.04-4.02 (m, 2H), 3.80-3.78 (m, 2H), 3.64-3.61 (m, 4H), 3.52-3.50 (m, 2H), 
2.81 (m, 2H). 2H peaks missing. 13C-NMR (CD3OD): δ 153.31, 142.05, 
118.03, 116.71, 73.47, 71.63, 71.23, 70.98, 69.21, 42.10. IR (cm-1): ν 
519.4, 749.43, 826.53, 927.78, 1064.9, 1109.42, 1237.39, 1297.79, 
1351.55, 1456. MS (HR-LCMS, ESI+): found 241.1546 [M+H]+, 
C12H21N2O3 requires 241.1547. 
Synthesis of 17-(4-aminophenoxy)-3,6,9,12,15-pentaoxaheptadecan-
1-amine 17. To a solution of nitrobenzene 15 (1.541 g, 3.6 mmol) in 
methanol (78 mL) was added PtO2 (16 mg, 0.072 mmol). The reaction 
mixture was stirred 24 hours at room temperature under an atmosphere of 
hydrogen and then filtered through a pad of celite. The filtrate was 
concentrated under reduced pressure to afford desired compound 17 as a 
colorless oil (1.245 g, 3.35 mmol, 93%). 1H-NMR (CDCl3): 6.72-6.70 (m, 
2H), 6.60-6.58 (m, 2H), 4.01 (m, 2H), 3.76 (m, 2H), 3.68-3.56 (m, 18H), 
3.45 (m, 2H), 2.82 (br. s, 2H). 1H peak missing. 13C-NMR (CDCl3): 151.82, 
140.30, 116.28, 115.83, 70.72, 70.58, 70.55, 70.25, 70.24, 69.89, 41.72. 
Peaks missing due to overlaps in the PEG region. IR (cm-1): ν 519.18, 
772.2, 827.74, 947.61, 1105.32, 1237.07, 1349.97, 1455.91, 1511.27, 
1675.79, 2869.65, 3352.59. MS (HR-LCMS, ESI+): found 373.2330 
[M+H]+, C18H33N2O6 requires 373.2333.  
Synthesis of tert-butyl (2-(2-(2-(4-
aminophenoxy)ethoxy)ethoxy)ethyl)carbamate 4. To a solution of 
aniline 16 (950 mg, 3.95 mmol) in anhydrous THF (10 mL) was added di-
tert-butyl dicarbonate (863 mg, 3.95 mmol). The resulting solution was 
stirred under argon for 15 hours at room temperature, concentrated under 
reduced pressure and purified by silica gel chromatography (SiO2 150 mL, 
cyclohexane/ethyl acetate 5:5 to 0:10) to afford desired mono-protected 
derivative 4 (881 mg, 2.59 mmol, 66%) as a colorless oil (bis-Boc protected 
derivative has not been detected). 1H-NMR (DMSO-D6): δ 6.77 (t, 1H, 
J=6.0 Hz), 6.64 (d, 2H, J=8.1 Hz), 6.50 (d, 2H, J=8.1 Hz), 4.70 (s, 2H), 
3.93-3.90 (m, 2H), 3.67-3.65 (m, 2H), 3.57-3.55 (m, 2H), 3.51-3.49 (m, 2H), 
3.37 (t, 2H, J=6.0 Hz), 3.06 (q, 2H, J=6.0 Hz), 1.37 (s, 9H). 13C-NMR 
(DMSO-D6): δ 155.59, 149.25, 115.34, 115.02, 118.03, 77.59, 69.84, 
69.52, 69.18, 67.54, 40.21, 28.24. Peaks missing due to overlaps in the 
PEG region (at 69.18 ppm). IR (cm-1): ν 473.07, 516.98, 641.28, 755.71, 
781.48, 825.28, 942.46, 1065.3, 1107.17, 1124.99, 1170.83, 1238.96, 
1274.03, 1331.27, 1365.8, 1391.52, 1455.85, 1511.04, 1629.86, 1702, 
2871.74, 2928.71, 2975.02, 3355.18. MS (HR-LCMS, ESI+): found 
341.2069 [M+H]+, C17H29N2O5 requires 341.2071.  
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Synthesis of tert-butyl (17-(4-aminophenoxy)-3,6,9,12,15-
pentaoxaheptadecyl)carbamate 5 and tert-butyl (4-((2,2-dimethyl-4-
oxo-3,8,11,14,17,20-hexaoxa-5-azadocosan-22-
yl)oxy)phenyl)carbamate 18. To a solution of aniline 17 (1.250 g, 3.4 
mmol) in anhydrous THF (10 mL) was added di-tertbutyl dicarbonate (747 
mg, 3.4 mmol). The reaction mixture was stirred under argon for 16 h at 
room temperature. The solution was then concentrated under reduced 
pressure and the crude was purified by silica gel chromatography (SiO2 
200 mL, cyclohexane/ethyl acetate 5:5 to 0:10) to afford successively bis-
Boc protected derivative 18 as a colorless oil (127 mg, 0.221 mmol, 6%) 
and mono-protected derivative 5 as a colorless oil (1.105 g, 2.34 mmol, 
69%). 5: 1H-NMR (CDCl3): δ 6.73-6.71 (m, 2H), 6.62-6.60 (m, 2H), 5.09 
(br. s, 1H), 4.03-4.01 (m, 2H), 3.80-3.77 (m, 2H), 3.70-3.57 (m, 16H), 3.51-
3.49 (m, 2H), 3.31-3.25 (m, 2H), 1.42 (s, 9H). 1H peak missing. 13C-NMR 
(CDCl3): δ 156.08, 152.02, 140.01, 116.50, 115.87, 79.16, 70.79, 70.65, 
70.60, 70.55, 70.25, 65.94, 68.15, 40.39, 28.48. Peaks missing due to 
overlaps in the PEG region. IR (cm-1): ν 516.85, 757.04, 775.92, 824.36, 
947.62, 1098.6, 1169.28, 1236.93, 1272.65, 1328.42, 1350.31, 1365.04, 
1391.08, 1455.33, 1509.91, 1630.07, 1704.37, 2868.94, 3354.6. MS (HR-
LCMS, ESI+): found 473.2856 [M+H]+, C23H41N2O8 requires 473.2857. 16: 
1H-NMR (CDCl3): δ 7.23 (m, 2H), 6.83 (m, 2H), 6.45 (br. s., 1H), 5.05 (br. 
s., 1H), 4.08 (m, 2H), 3.82 (m, 2H), 3.69-3.50 (m, 18H), 3.29 (m, 2H), 1.49 
(s, 9H), 1.43 (s, 9H). 13C-NMR (CDCl3): δ 156.14, 154.89, 153.26, 131.78, 
120.50, 115.14, 80.32, 79.26, 70.90, 70.72, 70.69, 70.61, 70.33, 69.87, 
67.87, 40.45, 28.54, 28.48. Peaks missing due to overlaps in the PEG 
region. IR (cm-1): ν 522.76, 734.89, 774.4, 804.07, 830.08, 948.02, 
1011.64, 1027.11, 1049.96, 1103.5, 1158.47, 1228.45, 1365.49, 1391.43, 
1412.49, 1454.67, 1512.62, 1712.79, 2870.2, 2974.04. MS (HR-LCMS, 
ESI+): found 573.3382 [M+H]+, C28H49N2O10 requires 573.3382.  
Synthesis of Fe-filled-CNTs-TEG-Boc 19. To a dispersion of Fe filled-
CNTs (200 mg) in NMP (90 mL), obtained by 20 min of sonication, was 
added a solution of aniline 4 (144 mg, 0.423 mmol) in NMP (10 mL). After 
15 min of sonication isoamyl nitrite (192 μL, 1.438 mmol) was added and 
the reaction stirred at 90 °C for 20 hours. The reaction mixture was filtered 
on fluoropore filter, the precipitate washed with ethyl acetate (50 mL) and 
dispersed in AcOEt by 1 min of sonication and filtered again on fluoropore. 
Three cycles of filtration-dispersion-filtration followed by washing with 
acetone and removal of the solvents under reduced pressure afforded 
desired compound as a black powder (195 mg). The complete 
characterization of this material is presented under Results and Discussion 
section.  
Synthesis of Fe-filled-CNTs-HEG-Boc 20. To a dispersion of Fe filled-
CNTs (600 mg) in NMP (290 mL), obtained by 20 min of sonication, was 
added a solution of aniline 5 (600 mg, 1.27 mmol) in NMP (10 mL). After 
15 min of sonication isoamyl nitrite (578 μL, 4.32 mmol) was added and 
the reaction stirred at 90 °C for 20 hours The reaction mixture was filtered 
through fluoropore filters, the filtrate washed with ethyl acetate (50 mL), re-
dispersed in ethyl acetate (100 mL) by 1 min of sonication and filtered 
again on fluoropore filters. Three cycles of filtration-redispersion-filtration 
followed by washing with acetone and removal of the solvents under 
reduced pressure afforded desired compound as a black powder (511 mg). 
The complete characterization of this material is presented under Results 
and Discussion section. 
Synthesis of Fe filled-CNTs-TEG-NH2 21. To a dispersion of Fe-filled-
CNTs-TEG-Boc 19 (150 mg) in methanol (263 mL), obtained by 10 min of 
sonication, was added under vigorous stirring a concentrated 12 N HCl 
solution (37.5 mL) and the reaction stirred at room temperature for 16 
hours. The reaction mixture was poured into water (250 mL) and the 
precipitate formed filtered on an omnipore filter, re-dispersed in methanol 
(25 mL), poured in water (100 mL) and filtered again on omnipore. Three 
successive filtration-redispersion-filtration cycles followed by a last 
washing with small amounts of methanol afforded desired compound as a 
black powder (150 mg). The complete characterization of this material is 
presented under Results and Discussion section.  
Synthesis of Fe-filled-CNTs-HEG-NH2 22. To a dispersion of Fe-filled-
CNTs-HEG-Boc 20 (300 mg) in methanol (525 mL), obtained by 10 min of 
sonication, was added a concentrated 12 N HCl solution (75 mL) under 
vigorous stirring and the reaction stirred at room temperature for 16 h. The 
reaction mixture was poured into water (200 mL), the precipitate formed 
filtered on an omnipore filter, re-dispersed in methanol (50 mL), poured in 
water (200 mL) and filtered again on omnipore. Three successive filtration-
redispersion-filtration cycles followed by a last washing with small amounts 
of methanol afforded desired compound as a black powder (290 mg). The 
complete characterization of this material is presented under Results and 
Discussion section.  
Synthesis of dioxopyrrolidin-1-yl 2-(4-(3-(2-(furan-2-yl)-8-methyl-8H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-
yl)ureido)phenyl)acetate 23. In a flask under argon containing PTP-
COOH 1 (25 mg, 0.0578 mmol), N-hydroxysuccinimide (27 mg, 0.231 
mmol), EDC·HCl (44.3 mg, 0.231 mmol) and DMAP (28.2 mg, 0.231 mmol) 
was added via syringe anhydrous DMF. The reaction mixture was 
sonicated for 30 sec, stirred for 48 hours at room temperature, 
concentrated under reduced pressure and diluted with water (25 mL) and 
ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate 
(2 × 50 mL), the combined organic layers dried over magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude was purified 
by silica gel chromatography (SiO2 100 mL, ethyl acetate /acetonitrile 10:0 
to 6:4) to afford desired compound 23 as a white solid (14 mg, 0.026 mmol, 
44 %). This compound tends to quickly hydrolyze. As a consequence, it 
was kept under argon at -22 °C, always synthesized on the strictly 
necessary amounts and engaged as soon as possible in the next reaction. 
M.p.: 177°C (decomposition). 1H-NMR (DMSO-D6): 10.68 (s, 1H), 9.73 (s, 
1H), 8.79 (s, 1H), 7.98 (dd, 1H, J1=1.6, J2=0.7), 7.57 (d, 2H, J=8.2 Hz), 
7.37 (d, 2H, J=8.2 Hz), 7.30 (dd, 1H, J1=3.4, J2=0.7), 6.76 (dd, 1H, J1=3.4, 
J2=1.6), 4.14 (s, 3H), 4.09 (s, 2H), 2.82 (s, 4H). IR (cm-1): ν 472.53, 595.42, 
646.37, 762.03, 813.29, 905.03, 974.76, 1014.53, 1068.35, 1120.7, 
1186.49, 1207.38, 1237.48, 1317.96, 1422.21, 1511.97, 1612.15, 1673.64, 
1736.93, 1782.93, 1812.67, 2853.87, 2924.14, 3126.64. MS (HR-LCMS, 
ESI+): found 530.1533 [M+H]+, C24H20N9O6 requires 530.1531. Found 
447.1524 [M-OSu+OMe+H]+, C21H19N8O4 requires 447.1529.  
Synthesis of Fe-filled-CNTs-TEG-PTP 2. To a dispersion of Fe filled 
CNTs-TEG-NH2 (21, 30 mg) in anhydrous DMF (4mL), obtained by 10 min 
of sonication, were added succinimidic activated ester 23 (10 mg, 0.019 
mmol) and triethylamine (10 μL, 0.072 mmol). The reaction mixture was 
sonicated 5 min more and stirred at room temperature for 14 hours, filtered 
on omnipore and rinsed with DMF (10 mL). The precipitate re-dispersed 
by 1 min of sonication in methanol and filtered again. Three cycles of 
redispersion-filtration afforded desired material as a black powder (29 mg). 
The complete characterization of this material is presented under Results 
and Discussion section.  
Synthesis of Fe-filled-CNTs-HEG-PTP 3. To a dispersion of Fe filled 
CNTs-HEG-NH2 (22, 30 mg) in anhydrous DMF (6mL), obtained by 10 min 
of sonication, were added activated succinimidic ester 23 (10 mg, 0.019 
mmol) and triethylamine (10 μL, 0.072 mmol). The reaction mixture was 
sonicated 5 min more, stirred at room temperature for 14 hours, filtered 
through omnipore and rinsed with DMF (10 mL) and the precipitate was 
re-dispersed by 1 min of sonication in methanol and filtered again. Three 
cycles of redispersion-filtration afforded desired material as a black 
powder (31 mg). The complete characterization of this material is 
presented under Results and Discussion section.  
Radioligand competition experiments. Radioligand binding experiment 
with [3H]HEMADO were performed according to previously reported 
procedures.[49,50] Parts of the detailed protocol are reproduced here:  
Crude membranes for radioligand binding experiments were prepared by 
thawing frozen A3AR-overexpressing CHO cells followed by scraping them 
off the petri dishes in ice-cold hypotonic buffer (5mM Tris/HCl, 2 mM EDTA, 
pH 7.4). The cell suspension was homogenized on ice (Ultra-Turrax, 2 X 
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15 s at full speed) and the homogenate was spun for 10 min (4 °C) at 1,000 
g. The supernatant was then centrifuged for 30 min at 100,000 g. The 
membrane pellet was resuspended in 50 mM Tris/HCl, 10 mM MgCl2, 1 
mM EDTA, pH 8.25, frozen in liquid nitrogen at a protein concentration of 
1–3 mg·ml-1 and stored at -80 °C. For incubation and separation of bound 
from free radioligand a 96-well microplate filtration system with built in filter 
bottoms (Millipore Multiscreen MAFC) was used.[49] Competitions binding 
studies were done at a concentration of 1 nM of [3H]HEMADO, incubated 
in duplicates with different concentrations (0.3, 1, 3 and 10 μM) of Fe filled-
CNTs-PEG-PTP (2,3), Fe filled-CNTs-PEG-NH2 (21,22) or TEG-PTP 6 
and HEG-PTP 7 for 3 hours at 25 °C (for CNTs, the concentrations are 
based on calculated PTP content or on the same weight amount as for the 
derivatized material for control Fe filled-CNTs-PEG-NH2 (21,22)). The 
samples were then filtered through the built-in filter at the bottom of the 
wells and washed three times with 200 μL of ice-cold binding buffer. After 
addition of 20 μL of scintillator to the dried filter plates samples were 
counted in a beta counter. Ki values were calculated from competition 
curves by nonlinear curve fitting with the program Prism 6 (GraphPad 
Software).  
Magnetic cell sorting. 400 μL of a 430,000 cells∙mL-1 suspension in 
complete CO2 independent medium was added to 113 μL of Fe filled-
CNTs-HEG-PTP (3) (dispersed at a constant concentration of 1200 μg∙mL-
1 by 60 sec of sonication in complete CO2 independent medium). The 
resulting mixture was diluted to 1000 µL with complete CO2 independent 
medium and mixed for 10 min in a plastic vial, giving a final concentration 
of 215,000 cells∙mL-1 and 172 μg CNTs∙mL-1. Then, a Ne-B permanent 
magnet (4X4X2 cm, Supermagnete) was placed against the vial and 100 
μL supernatant aliquots were removed after 1, 2, 4 and 8 min of magnetic 
sorting. These aliquots were centrifuged in eppendorfs (3 min, 5000 rpm). 
The first 75 μL of the supernatant were discarded and the remaining pellet 
(25 μL) was re-dispersed. Cells in this pellet were counted (and imaged) 
in a Neubauer chamber.  
Magnetic sorting of a mixture of CHO wild-type and CHO A3 cells. 5 
μL of fluorescent dye (DII for CHO A3, red, DIO for CHO WT, green) were 
added to 1 mL of 1,500,000 cells∙mL-1 CHO WT or CHO A3 cells 
suspension in CO2 independent medium. After 25 min of agitation on a 
planetary rotator at 37 °C protected from light, the two samples were 
subjected to three cycles of centrifugation at 1500 rpm for 5 min. After 
medium removal and resuspension in 1 mL of CO2 independent medium, 
the cells were counted, re-adjusted to 1,500,000 cells∙mL-1, and used for 
the magnetic filtration test. In a 1.5 plastic vial, 250 μL of the CHO WT cells 
suspension, 250 μL of the CHO A3 cells suspension and 250 μL of a 1200 
μg∙mL-1 dispersion of Fe filled-CNTs-HEG-PTP (3) were mixed with 250 
μL of CO2 independent medium, giving a total volume of 1 mL and final 
cell densities of 375,000 A431 cells∙mL-1, 375,000 EA cells∙mL-1 and a 
CNTs concentration of 300 μg∙mL-1. 200 μL of this solution were withdrawn 
at t0 for the confocal analysis. The cell suspension was then agitated for 
10 min. Then, a Ne-B permanent magnet (4X4X2 cm, Supermagnete) was 
placed against the vial and 200 μL of supernatant were removed after 8 
min of magnetic sorting for confocal analysis. After complete removal of 
the supernatant, the magnetic precipitate was re-dispersed in 400 μL of 
CO2 independent medium and used for confocal analysis. 
Computational Studies. CNT coordinates were modeled by using 
Nanotube builder tool of VMD package as a single wall, uncapped at the 
terminal, and empty nanotube.[64] A segment of a nanotube of 35 nm in 
length was generated by setting chiral indexes, n and m, to 60 and 60 
respectively. The CNT was then functionalized with the spacers and the 
PTP derivative with MOE modeling suite.[65] A previously proposed 
homology model of the hA3AR based on the crystallographic structure of 
hA2AAR in complex with the antagonist ZM241385 (PDB code: 3EML)  was 
used for modeling studies.[66,67]  
The PTP derivative coordinates inside the hA3AR binding site were 
obtained by a molecular docking simulation with GOLD protocol according 
to previous studies on the binding mode of PTP based antagonist.[47,68] 
The CNT were manually placed in the proximity of the linkers and 
connected to reproduce the synthesis route. A series of minimizations was 
then performed on the linker and successively on the system with MOE 
minimization tool adopting amber10:ETH force field.  Finally, the receptor-
CNTs-PEG-PTP complex was embedded in a 1-palmitoyl-2oleyl-sn-
glycerol-3-phospho-choline (POPC) lipid bilayer, based on the pre-
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A3 adenosine receptor ligands conjugated to Fe-filled carbon nanotubes were developed with the aim to target specific cancer cell lines 
for cancer magnetic cell sorting and thermal therapy. The nanostructure was able to efficiently bind to A3 adenosine receptors, 
unfortunately, when interfaced with cells, the conjugates did not displayed selectivity for those overexpressing the receptor.  
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